Patent Application
20060110798
The present invention relates to in vitro cells, and more particularly to cells expressing a recombinase that are useful in production of adenovirus vectors, and to methods of production of such cells.
Application Ser. No. 08/250,885, filed on May 31, 1994 and its parent application Ser. No. 08/080,727 disclose and claim a genus of adenovirus (Ad)-derived cell expression vectors having excellent potential as live recombinant vaccines and as transducing vectors for gene therapy. In the human Ad genome, early region 1 (E1), E3, and a site upstream of E4 have been utilized as sites for introducing foreign DNA sequences to generate adenovirus recombinants. In the absence of compensating deletions in E1 or E3, a maximum of about 2 kb can be inserted into the Ad genome to generate viable virus progeny. The E1 regions is not required for viral replication in complementing 293 cells and tip to 3.2 kb can be deleted in this region to generate conditional helper independent vectors with a capacity of 5.0-5.2 kb. In the E3 region, which is not required for viral replication in cultured cells, deletions of various sizes have been utilized to generate nonconditional helper independent vectors with a capacity of up to 4.5-4.7 kb.
The maximum capacity for inserts of foreign DNA in currently available helper independent Ad vectors such as those described in the parent applications is approximately 8 kb. This limited capacity arises from the use of Ad vectors which have deletions of E1 and E3 sequences and from the fact that most other regions of the viral genome must be retained in order that the viral vector may be propagated without the need for a helper virus.
Besides this limited capacity for insert DNA, previous vectors retain most of the viral genome, making it possible for expression of viral genes in transduced cells or in inoculated animals, including humans, which can result in toxic or other untoward effects. In addition, previous viral vectors can recombine with Ad sequences present in cells used for propagation of the vectors or with Ad sequences that may be present in inoculated animals. Therefore, it is an objective of this invention to provide Ad cloning vectors from which all or most viral genes have been removed and which have increased safety and capacity for larger insertions compared to currently available vectors.
This invention provides a simple and useful system by which high capacity Ad5 cloning vectors may be developed. As demonstrated in application Ser. No. 08/486,549, entitled “Adenoviruses for Control of Gene Expression”, provision of Cre recombinase in Ad infected cells can catalyze excision or rearrangement of viral DNA sequences that contain the target sites (loxP) for Cre mediated site specific recombination. In the present invention, use is made of this knowledge to construct Ad5 genomes in which the viral DNA packaging signals can be excised from the viral genome by action of Cre, FLP or other recombinase. Said excision of said packaging signal results in a viral DNA that is unable to package into virion particles. Such a viral DNA, though unable to package into virions, may encode viral functions that provide complementing functions for replication of a second, viral “vector”, that lacks substantial portions of the viral genome so that in coinfected cells, though both helper and vector DNAs may replicate, only the vector DNA can be packaged into virions.
One embodiment of the present invention provides a bacterial plasmid comprising a circularized modified human adenovirus type 5 (Ad5) or other adenoviral genome that contains sequences that can be recognized and acted upon by a site specific recombinase known as Cre, FLP, or any other known recombinase which specifically recognizes a target recombination site. Said bacterial plasmid is able to generate infectious Ad5 carrying the modified sequences including the sequences that can be recognized by the site-specific recombinase. The structure of the modified sequences in the bacterial plasmid and in viruses generated from said plasmid is such that recombination catalyzed by the site-specific recombinase results in excision of sequences, known as the packaging signal, near the left end of the Ad5 genome, that are required for packaging of Ad5 or other adenoviral DNA into infectious virion particles. Optionally, certain regions of the plasmid and resulting viruses may be deleted, such as sequences from E1 or E3 that can be omitted from the viral genome without preventing the viral genome from replicating in such cells as may be permissive for replication of said viral genome in the form of infectious virus.
A second embodiment of the invention provides a bacterial plasmid comprising approximately 340 base pairs from the left end of the Ad5 or other adenoviral genome, including the left end terminal repeat sequences of said genome and the packaging signal sequences thereof and the right terminal repeat sequences of the Ad5 or other adenoviral genome. The left end of the left terminal repeat sequence is joined in “head to tail” configuration with the right end of the right terminal repeat viral DNA sequences. DNA sequences between approximately nucleotide 340 near the left end and approximately nucleotide 35,800 near the right end of the genome, are substituted with restriction enzyme sites suitable for insertion of foreign DNA sequences of up to about 35,000 base pairs in length. Naturally, those skilled in the art will appreciate from this disclosure that other configurations may be used, such as that illustrated in
A third embodiment of the invention provides a bacterial plasmid comprising approximately 340 base pairs from the left end of the Ad5 or other adenoviral genome, including the left end terminal repeat sequences of said genome and the packaging signal sequences thereof and the right terminal repeat sequences of the Ad5 or other adenoviral genome. The left end of the left terminal repeat sequence and the right end of the right terminal repeat sequence are joined to plasmid DNA sequences and can be cleaved from said plasmid DNA sequences by restriction enzyme digestion. Viral DNA sequences between approximately nucleotide 340 near the left end and approximately nucleotide 35,800 near the right end of the genome, are substituted with restriction enzyme sites suitable for insertion of foreign DNA sequences of up to about 35,000 base pairs in length.
A fourth embodiment of the invention provides a mammalian cell line, such as a human cell line, that expresses a recombinase enzyme such as Cre, FLP, combinations thereof or other recombinases. Alternatively, Cre; FLP or other site-specific recombinase functions may be provided by an Ad5 or other adenoviral derived vector that expresses the recombinase in suitable cells.
Other embodiments of the present invention include Ad genome constructs, known as “vectors”, containing substantial deletions of viral DNA sequences that are substituted with large insertions of foreign DNA, 20-35 kb in length. Such genomes are unable to replicate as viruses in the absence of viral products provided by a second virus, hereafter called a “helper” virus.
One specific embodiment of the invention is a helper virus that can be designed, propagated, and used in such a way that when employed to support replication of a second virus, the vector, from which substantial portions of the viral genome have been deleted and substituted with foreign DNA, said “helper” virus DNA is unable to be packaged into infectious virions.
Any publications referenced herein are hereby incorporated by reference in this publication in order to more fully describe the state of the art to which the present invention pertains.
It is important to an understanding of the present invention to note that all technical and scientific terms used herein, unless otherwise defined, are intended to have the same meaning as commonly understood by one of ordinary skill in the art. The techniques employed herein are also those that are known to one of ordinary skill in the art, unless stated otherwise.
Reference to particular buffers, media, reagents, cells, culture conditions and the like, or to some subclass of same, is not intended to be limiting, but should be read to include all such related materials that one of ordinary skill in the art would recognize as being of interest or value in the particular context in which that discussion is presented. For example, it is often possible to substitute one buffer system or culture medium for another, such that a different but known way is used to achieve the same goals as those to which the use of a suggested method, material or composition is directed.
The terms used herein are not intended to be limiting of the invention. For example, the term “gene” includes cDNAs, RNA, or other polynucleotides that encode gene products. “Foreign gene” denotes a gene that has been obtained from an organism or cell type other than the organism or cell type in which it is expressed; it also refers to a gene from the same organism that has been translocated from its normal situs in the genome. In rising the terms “nucleic acid”, “RNA”, “DNA”, etc., we do not mean to limit the chemical structures that can be used in particular steps. For example, it is well known to those skilled in the art that RNA can generally be substituted for DNA, and as such, the use of the term “DNA” should be read to include this substitution. In addition, it is known that a variety of nucleic acid analogues and derivatives is also within the scope of the present invention. “Expression” of a gene or nucleic acid encompasses not only cellular gene expression, but also the transcription and translation of nucleic acid(s) in cloning systems and in any other context. The term “recombinase” encompasses enzymes that induce, mediate or facilitate recombination, and other nucleic acid modifying enzymes that cause, mediate or facilitate the rearrangement of a nucleic acid sequence, or the excision or insertion of a first nucleic acid sequence from or into a second nucleic acid sequence. The “target site” of a recombinase is the nucleic acid sequence or region that is recognized (e.g., specifically binds to) and/or acted upon (excised, cut or induced to recombine) by the recombinase. The term “gene product” refers primarily to proteins and polypeptides encoded by other nucleic acids (e.g., non-coding and regulatory RNAs such as tRNA, sRNPs). The term “regulation of expression” refers to events or molecules that increase or decrease the synthesis, degradation, availability or activity of a given gene product.
The present invention is also not limited to the use of the cell types and cell lines used herein. Cells from different tissues (breast epithelium, colon, lymphocytes, etc.) or different species (human, mouse, etc.) are also useful in the present invention.
It is important in this invention to detect the generation and expression of recombinant nucleic acids and their encoded gene products. The detection methods used herein include, for example, cloning and sequencing, ligation of oligonucleotides, use of the polymerase chain reaction and variations thereof (e.g., a PCR that uses 7-deaza GTP), use of single nucleotide primer-guided extension assays, hybridization techniques using target-specific oligonucleotides that can be shown to preferentially bind to complementary sequences under given stringency conditions, and sandwich hybridization methods.
Sequencing may be carried out with commercially available automated sequencers utilizing labeled primers or terminators, or using sequencing gel-based methods. Sequence analysis is also carried out by methods based on ligation of oligonucleotide sequences which anneal immediately adjacent to each other on a target DNA or RNA molecule (Wu and Wallace, Genomics 4: 560-569 (1989); Landren et al., Proc. Natl. Acad. Sci. 87: 8923-8927 (1990); Barany, F., Proc. Natl. Acad. Sci. 88: 189-193 (1991)). Ligase-mediated covalent attachment occurs only when the oligonucleotides are correctly base-paired. The Ligase Chain Reaction (LCR), which utilizes the thermostable Taq ligase for target amplification, is particularly useful for interrogating late onset diabetes mutation loci. The elevated reaction temperatures permits the ligation reaction to be conducted with high stringency (Barany, F., PCR Methods and Applications 1: 5-16 (1991)).
The hybridization reactions may be carried out in a filter-based format, in which the target nucleic acids are immobilized on nitrocellulose or nylon membranes and probed with oligonucleotide probes. Any of the known hybridization formats may be used, including Southern blots, slot blots, “reverse” dot blots, solution hybridization, solid support based sandwich hybridization, bead-based, silicon chip-based and microtiter well-based hybridization formats.
The detection oligonucleotide probes range in size between 10- 1,000 bases. In order to obtain the required target discrimination using the detection oligonucleotide probes, the hybridization reactions are generally run between 20°-60° C., and most preferably between 30°-50° C. As known to those skilled in the art, optimal discrimination between perfect and mismatched duplexes is obtained by manipulating the temperature and/or salt concentrations or inclusion of formanide in the stringency washes.
The cloning and expression vectors described herein are introduced into cells or tissues by any one of a variety of known methods within the art. Such methods are described for example in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1992), which is hereby incorporated by references, and in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1989), which is also hereby incorporated by reference. The methods include, for example, stable or transient transfection, lipofection, electroporation and infection with recombinant viral vectors.
The protein products of recombined and unrecombined coding sequences may be analyzed using immune techniques. For example, a protein, or a fragment thereof is injected into a host animal along with an adjuvant so as to generate an immune response. Immunoglobulins which bind the recombinant fragment are harvested as an antiserum, and are optionally further purified by affinity chromatography or other means. Additionally, spleen cells may be harvested from an immunized mouse host and fused to myeloma cells to produce a bank of antibody-secreting hybridoma cells. The bank of hybridomas is screened for clones that secrete immunoglobulins which bind to the variant polypeptides but poorly or not at all to wild-type polypeptides are selected, either by pre-absorption with wild-type proteins or by screening of hybridoma cell lines for specific idiotypes that bind the variant, but not wild-type, polypeptides. Nucleic acid sequences capable of ultimately expressing the desired variant polypeptides are formed from a variety of different polynucleotides (genomic or cDNA, RNA, synthetic olignucleotides, etc.) as well as by a variety of different techniques.
The DNA sequences are expressed in hosts after the sequences have been operably linked to (i.e., positioned to ensure the functioning on an expression control sequence. These expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors contain selection markers (e.g., markers based on tetracycline resistance or hygromycin resistance) to permit detection and/or selection of those cells transformed with the desired DNA sequences. Further details can be found in U.S. Pat. No. 4,704,362.
Polynucleotides encoding a variant polypeptide include sequences that facilitate transcription (expression sequences) and translation of the coding sequences such that the encoded polypeptide product is produced. Construction of such polynucleotides is well known in the art.
For example, such polynucleotides include a promoter, a transcription termination site (polyadenylation site in eukaryotic expression hosts), a ribosome binding site, and, optionally, an enhancer for use in eukaryotic expression hosts, and optionally, sequences necessary for replication of a vector.
E. coli is one prokaryotic host useful particularly for cloning DNA sequences of the present invention. Other microbial hosts suitable for use include bacilli, such as Bacillus subtilus, and other enterobacteriaceae, such as Salmonella, Serratia, and various Pseudomonus species. Expression vectors are made in these prokaryotic hosts which will typically contain expression control sequences compatible with the host cell (e.g., an origin of replication). In addition, any number of a variety of well-known promoters are used, such as the lactose promoter system, a tryptophan (Trp) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda. The promoters typically control expression, optionally with an operator sequence, and have ribosome binding site sequences, for example, for initiating and completing transcription and translation.
Other microbes, such as yeast, are used for expression. Saccharomyces is a suitable host, with suitable vectors having expression control sequences, such a promoters, including 3-phosphoglycerate kinase or other glycotic enzymes, and an origin of replication, termination sequences, etc. as desired.
In addition to microorganisms, mammalian tissue cell culture is used to express and produce the polypeptides of the present invention. Eukaryotic cells are preferred, because a number of suitable host cell lines capable of secreting intact human proteins have been developed in the art, and include the CHO cell lines, various COS cell lines, HeLa cells, myeloma cell lines, Jurkat cells, and so forth. Expression vectors for these cells include expression control sequences, such as an origin of replication, a promoter, an enhancer, and necessary information processing sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Preferred expression control sequences are promoters derived from immunoglobin genes, SV40, Adenovirus, Bovine Papilloma Virus, and so forth. The vectors containing the DNA segments of interest (e.g., polypeptides encoding a variant polypeptide) are transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment or electroporation is useful for other cellular hosts.
The method lends itself readily to the formulation of test kits for use in diagnosis. Such a kit comprises a carrier compartmentalized to receive in close confinement one or more containers wherein a first container contains reagents useful in the localization of the labeled probes, such as enzyme substrates. Still other containers contain restriction enzymes, buffers etc., together with instructions for use.
The recombinant Ad vectors described herein are significantly different from previously described constructs. They combine the use of vectors having deletions of all or most of the viral genes with helper viruses that are designed so that, when used in coinfections with vector viruses, said helper viruses are able to complement the growth of the vectors but are unable to package their viral DNA into infectious virions. Thus vector viruses can be prepared substantially free of helper virus.
For viral DNA replication and packaging of viral DNA into virion particles, only three regions of the viral DNA are known to be required in cis. These are the left inverted terminal repeat, or ITR, (bp 1 to approximately 103) the packaging signals (approximately 194 to 358 bp) (Hearing and Shenk, 1983, Cell 33: 695-703; Grable and Hearing 1992, J. Virol. 64: 2047-2056) and the right ITR. All other regions of the viral genome appear to be required only to produce viral products that act in trans to allow viral replication and production of infectious viruses. Thus if all essential viral proteins and RNA could be provided by a helper virus, a vector could be designed and constructed that could have most of the viral DNA deleted save for those sequences mentioned above that are required in cis for viral DNA replication and packaging.
A problem with helper dependent vectors has been that preparations of such vectors are invariably contaminated with helper virus and it is technically very difficult to separate the helper from the vector. In the main embodiments of the present invention, the helper virus is designed to have two lox P sites, two FRT sites or like recombinase recognition target sites near the left end of the genome, one inserted at approximately 189 bp from the extreme left end of the viral DNA, and the second, in parallel orientation with the first, situated rightward of the packaging signals, ie rightward of bp 358 (diagrammed in
In one embodiment of the invention, the helper virus is derived from a plasmid similar to those described in the parent applications and as illustrated in
As described herein and in prior applications from which this application claims priority with regard to the Cre/lox system, site specific recombination can be used lo specifically excise the packaging signal from the DNA of an adenovirus (designated as a helper virus) in cells expressing Cre recombinase and infected with said helper virus. Because removal of the packaging signal does not interfere with viral DNA replication and transcription, said helper virus genome can undergo replication and can express viral proteins that allow for replication and encapsidation of DNA of a second virus, a vector (designated a helper dependent vector), that contains the inverted terminal repeat sequences and packaging signal which are the only viral DNA sequences required in cis for DNA replication and encapsidation. Thus, said helper dependent vector can have all or most of the viral coding sequences deleted and substituted with foreign DNA and said vector can be propagated in Cre expressing host cells coinfected with the said helper virus and the resulting vector preparations are substantially free of helper virus. The present patent disclosure demonstrates that the FLP recombinase, which recognizes a nucleic acid site known as FRT (O'Gorman, S., Fox, D. T. and Wahl, G. M. Recombinase-mediated gene activation and site specific integration in mammalian cell. Science 251: 1351-1355, 1991; Senecoff, J. F., Rossmeissl, P. J. and Cox, M. M., DNA recognition by the FLP recombinase of the yeast 2μ plasmid, J. Mol. Biol. 201: 405-421, 1988) may be used in similar fashion. It will be appreciated by those skilled in the art based on this disclosure that the method is not limited to the use of Cre recombinase and its recognition sites and FLP and its recognition sites, as other site specific recombinases that act in similar fashion to Cre and FLP could be substituted for Cre or FLP recombinases, or used in combination with such enzymes.
In particular, such other site specific recombinases that act in similar fashion to Cre and FLP are recognized in the art to be identified as recombinases belonging to the integrase family of recombinases (also referred to as the lambda, or λ, integrase family). Members of the integrase family of recombinases are recognized in the art to comprise a distinct class of structurally related proteins. For example, Kilby et al. (Trends in Genetics, 9:413-421, 1993) state that three site specific recombinases, “cre, FLP and R1 all belong to the λ integrase family of recombinases and show striking similarities, not only in the types of reaction they can carry out, but also in the structure of their target sites and mechanism of recombination (
Another embodiment of the invention provides human cells, such as 293 cells, or other cells that may be deemed suitable in that they support the replication of the viral components of the invention, that stably express Cre, FLP or other recombinase, such as an integrase family recombinase, and that can be transfected with the plasmids described herein to generate a helper virus from which the packaging signals have been removed through excision mediated by Cre, FLP or other recombinases, such as integrase family recombinases. For example, it will be appreciated by those skilled in the art that the requisite cell lines can be generated by transfecting 293 cells or other cells with a plasmid comprising the coding sequence for Cre, FLP or other integrase family recombinase under the control of suitable regulatory sequences including a promoter and polyadenylation signal and containing in addition a selectable gene encoding, for example, resistance to G418 or histidinol. Based on the instant disclosure, a person skilled in the art can readily obtain drug resistant cells that will express the Cre, FLP or other integrase family recombinase in addition to the drug resistance gene used for selection.
As stated in application Ser. No. 08/250,855, filed May 31, 1994, vectors, optionally containing a foreign nucleic acid, may be “introduced” into a host cell, tissue or organism in accordance with known techniques, such as transformation, transfection using calcium phosphate-precipitated DNA, electroporation, gene guns, transfection with a recombinant virus or phagemid, infection with an infective viral particle, injection into tissues or microinjection of the DNA into cells or the like. Both prokaryotic and eukaryotic hosts may be employed, which may include bacteria, yeast, plants and animals, including human cells.
Once a given structural gene, cDNA or open reading frame has been introduced into the appropriate host, the host may be grown to express said structural gene, cDNA or open reading frame. Where the promoter is inducible, permissive conditions may be employed (for example, temperature change, exhaustion, or excess of a metabolic product or nutrient, or the like).
The expression vehicles used or provided herein may be included within a replication system for episomal maintenance in an appropriate cellular host, they may be provided without a replication system, or they may become integrated into the host genome.
While a wide variety of host cells are contemplated, certain embodiments require that the host cell express E1 sequences that are missing from or inactivated in the vector. While the human 293 cell line is the preferred host cell, the invention also contemplates other cell lines capable of complementing the vector having an E1 deletion. It is important to recognize that the present invention is not limited to the use of such cells as are used herein. Cells from different species (human, mouse, etc.) or different tissues (breast epithelium, colon, neuronal tissue, lymphocytes, etc.) may also be used.
To package larger inserts, it is necessary to first delete portions of the viral genome. Parts of region E1 can be deleted, and the resulting viruses can be propagated in human 293 cells.
Also, as stated in parent application Ser. No. 08/473,168, filed Jun. 7, 1995, another embodiment of the invention provides a mammalian cell line, such as a human cell line, that provides the Cre recombinase enzyme.
In another embodiment of the invention, a plasmid consisting of sequences comprising the left ITR, the packaging signal, and the right ITR, and optionally containing additional viral sequences can be readily obtained. An example, which is not meant lo be limiting, is illustrated in
In another embodiment of the invention, coreplication of helper virus comprising sequences derived from a plasmid such as pBG17Lox2 and a helper dependent virus comprising sequences derived from a plasmid such as pADHDV1 may be achieved by cotransfection of cells with said plasmids to generate replicating viral genomes. In the example illustrated in
In another embodiment of the invention, 293 cells or other human cells that do not express Cre, FLP or other recombinases, may be transfected with a plasmid such as that designated as pBG17Lox2 in
Having generally described this invention, as disclosed and claimed herein, the following specific exemplary support is provided to demonstrate the functionality of the disclosed and claimed system both in vitro and in vivo. However, this invention should not be interpreted as being limited to the specifics of the following examples. Rather, the scope of this invention should be determined through consultation of the claims appended hereto and equivalents thereof.
Experimental Synopsis and Conclusions Drawn:
Adenoviral (Ad) mediated in vivo gene transfer and expression are limited in part by cellular immune responses to viral-encoded proteins and/or transgene immunogenicity. In an attempt to diminish the former responses, we have previously developed and described helper-dependent (HD) Ad vectors in which the viral protein coding sequences are completely eliminated. These HD vectors have up to 37 kb insert capacity, are easily propagated in a Cre recombinase-based system, and can be produced to high concentration and purity (>99.9% helper-free vector). In this study, we compared safety and efficacy of leptin gene delivery mediated by an HD vector (HD-leptin) and a first-generation E1-deleted Ad vector (Ad-leptin) in normal lean and ob/ob (leptin-deficient) mice. In contrast to evidence of liver toxicity, inflammation, and cellular infiltration observed with Ad-leptin delivery in mice, HD-leptin delivery was associated with a significant improvement in associated safety/toxicity and resulted in efficient gene delivery, prolonged elevation of serum leptin levels, and associated weight loss. The greater safety, efficient gene delivery, and increased insert capacity of HD vectors are significant improvements over current Ad vectors and represent favorable features especially for clinical gene therapy applications.
Background for this Example:
Adenoviral (Ad) vectors are currently among the most efficient gene transfer vehicles for both in vitro and in vivo delivery, but the utilization of current Ad vectors for many gene therapy applications is limited by the transient nature of transgene expression obtained by these vectors (Stratford-Perricaudet, L. D., Levrero, M., Chasse, J., Perricaudet, M. & Briand, P. (1990) Hum. Gene Ther. 1, 241-256; Kay, M. A., Li, Q., Liu, R. J.-J., Leland, F., Roman C., Finegold, M. & Woo, S. L. C. (1992) Hum. Gene Ther. 3, 641-647.; Herz, J. & Gerard, R. D. (1993) Proc. Natl. Acad. Sci. USA 90, 2812-2816; Engelhardt, J. F., Simon, R. H., Yang, Y., Zepeda, M., Wber-Pendleton, S., Doranz, B., Grossman, M & Wilson, J. M. (1993) Hum. Gene Ther. 4, 757-769; Morsy, M. A., Alford, E. L., Bett, A., Graham, E. L. & Caskey, C. T. (1993) J. Clin. Invest. 92, 1580-1586; Morsy, M. A., Zhao, J. Z., Warman, A. W., O'Brien, W. E., Graham, F. L. & Caskey, C. T. (1996) J. Clin. Invest. 97, 826-832; Muzzin, P., Eisensmith, R. C., Copeland, K. C. & Woo, S. L. C. (1996) Proc. Natl. Acad. Sci. USA 93, 14804-14808). Several factors have been shown to contribute to and modulate the duration of Ad-mediated gene expression and the immunogenicity of these vectors, including “leaky” viral protein expression and the transgene that is delivered (Yang, Y., Nunes, F. A., Berencsi, K., Furth, E. E., Gonczol, E. & Wilson, J. M. (1994) Proc. Natl. Acad. Sci. USA 91, 4407-4411; Yang, Y., Ertl, H. D. & Wilson, J. M. (1995) J. Virol. 69, 2004-2015; Lochmuller, H., Petrof, B. J., Pari, G., Larochelle, N., Dodelet, V., Wang, Q., Allen, C., Prescott, S., Massie, B., Nalbantoglu, J., et al. (1996) Gene Ther. 3, 706-716; Gahery-Segard H., Juilliard, V., Gaston, J., Lengagne, R., Pavirani, A., Boulanger, P. & Guillet, J. G. (1997) Eur. J. Immunol. 27, 653-659; Kajiwara, K., Byrnes, A. P., Charlton, H. M., Wood, M. J. & Wood, K. J., (1997) Hum. Gene Ther. 8, 45-56; Kaplan, J. M., Armentano, D., Sparer, T. E., Wynn, S. G., Peterson, P. A., Wadsworth, S. C., Couture, K. K, Pennington, S. E., St. George, J. A., Gooding, L. R. & Smith, A. E. (1997) Hum. Gene Ther. 8, 45-46; Worgall, S., Wolff, G., Falck-Pedersen, E. & Crystal, R. G. (1997) Hum. Gene Ther. 8, 37-44; Tripathy, S. K., Black, H. B., Goldwasser, E. & Lieden, J. M. (1996) Natl. Med. 2, 545-550.). The development of Ad vectors that are deleted in all viral protein-coding sequences offers the prospect of a potentially safer, less immunogenic vector with an insert capacity of up to 37 kb (Mitani, K., Graham, F. L., Caskey, C. T. & Kochanek, S., (1995) Proc. Natl. Acad. Sci. USA 92, 3854-3858; Kochanek, S., Clemens, P. R., Mitani, K., Chen, H. H., Campbell, K. P. & Caskey, C. T. (1996) Proc. Natl. Acad. Sci. USA 93, 5731-5736; Clemens, P. R., Kochaneck, S., Sunada, Y., Chan, S., Chen, H. H., Campbell, K. P. & Caskey, C. T. (1996) Gene Ther. 3, 965-72; Chen, H. H., Mack, L. M., Kelly, R., Ontell, M., Kochanek, S. & Clemens, P. R. (1997) Proc. Natl. Acad. Sci. USA 94, 965-972; Fisher, K. J., Choi, H., Burda, J., Chen, S. & Wilson, J. M. (1996) Virology, 217, 11-22; Kumar-Singh, R. & Chamberlain, J. S. (1996) Hum. Mol. Gent. 5, 913-921; Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y. & Philipps, M. L., (1997) J. Virol. 71, 1842-1849; Lieber, A., He, C., Kirillova, I. & Kay, M. A. (1996) Virol. 70 8944-8960; Parks, R. J., Chen L., Anton, M., Sankar, U., Rudnicki, M. A. & Graham, F. L. (1996) Proc. Nail. Acad. Sci. USA 93, 13565-13570; Haecker, S. E., Stedman, H. H., Balice-Gordon, R. J., Smith, D. B., Greelish, J. P., Mitchell, M. A., Wells, A., Sweeney, H. L. & Wilson, J. M. (1996) Hum. Gen. Ther. 7, 1907-1914; Schiedner, G., Morral, N., Parks, R. J., Wu, Y., Koopmans, S. C., Langston, C., Graham, F. L., Beaudet, A. L. & Kochanek, S. (1998) Nat. Genet. 18, 180-183.). This vector is supplied in trans with the structural proteins required for packaging and rescue and is thus helper-dependent (HD) (Parks, R. J., Chen L., Anton, M., Sankar, U., Rudnicki, M. A. & Graham, F. L. (1996) Proc. Natl. Acad. Sci. USA 93, 13565-13570).
Leptin has been recently identified as a potent modulator of weight and food intake. Daily delivery of recombinant leptin protein was shown to induce weight reduction, supress appetite, and decrease blood insulin and glucose levels in ob/ob (leptin-deficient) mice (Halaas, J. L., Gajiwala, K. S., Maffei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D., Lallone, R. L., Burley, S. K. & Friedman, J. M. (1995) Science 269, 543-546; Pellymounter, M. A., Cullen, M. J., Hecht, R., Winters, D., Boone, T. & Collins, F. (1995) Science 269, 546-549; Campfield, L., A., Smith, F. J., Guisez, Y., Devos, R. & Burn, P. (1995) Science 269, 546-549.). It has been shown that delivery of the leptin cDNA by first-generation Ad vectors (Ad-leptin) may substitute for daily recombinant leptin protein treatment, although the elects were transient in both lean and ob/ob treated mice (Muzzin, P., Eisensmith, R. C., Copeland, K. C. & Woo, S. L. C. (1996) Proc. Avail. Acad. Sci. USA 93, 14804-14808; Morsy, M. A., Gu, M., Zhao, J. Z., Holder, D. J., Rogers, L. T., Pouch, W., Motzel, S. L., Klein, H. J., Gupta, S. K., Liang, X., et al. (1998) Gene Ther. 5, 8-18.). In the present study, we delivered the leptin cDNA using the HD virus (HD-leptin), testing the hypothesis that elimination of the viral protein coding sequences would diminish the vector's cellular immunogenicity and toxicity, and hence support its longevity in vivo. Because both the viral proteins and the transgene were factors implicated in the cellular immunogenicity of recombinant Ad viruses, we designed experiments to compare the HD and Ad vectors in ob/ob mice that are naïve to leptin (in which the protein is potentially immunogenic), as well as in lean mice that normally express leptin.
In this study, we show that HD-leptin provided greater safety as reflected by absence of liver toxicity, cellular infiltrates, extended longevity of gene-expression, and stability of vector DNA in livers of treated mice over that observed with Ad-leptin treatment.
Materials and Methods
Construction of Vectors.
Construction of Ad-leptin and Ad-β-galalactosidase (β-gal) recombinant vectors has been described (Morsy, M. A., Gu, M., Zhao, J. Z., Holder, D. J., Rogers, I. T., Pouch, W., Motzel, S. L., Klein, H. J., Gupta, S. K., Liang, X., et al. (1998) Gene Ther. 5, 8-18.). The expression cassettes contain the human cytomegalovirus (HCMV) promoter (Invitrogen), the transgene, and the bovine growth hormone poly(A) sequence. First generation vectors were propagated and titered as described (Graham, F. L., Smiley, J., Russell, W. C. & Nairn, R. (1977) J. Gen. Virol. 36, 59-72; Graham, F. L. & Prevec, L. (1991) in Gene Transfer and Expression Protocols., ed. Murray, E. J. (Humana, Clinton, N.J.), pp. 109-128.). The HD vector constructed for this study (HD-leptin) was prepared by releasing the linear backbone structure of HD-leptin from its plasmid pΔSTK120-HCMV-mOb-BGHpA (by PmeI digest) and transfecting the linear DNA into 293-cre4 cells followed by helper infection as described in HD-leptin propagation section below. Two different structures were used for rescuing HD viruses expressing leptin, HD-leptin (used in all the in vivo studies reported in this article), and HD-leptin-monomer. The structure of the HD-leptin plasmid is a pBluescript IIKS based plasmid that contains (in the following order) the Ad5 inverted terminal repeat (ITR) sequences and the packaging signal Ψ, 440 bp, (nucleotides 1-440): a 5,072-bp fragment of hypoxanthine guanine phosphoribosyltransferase (nucleotides 12,373-17,781 in gb:humhprtb); the leptin expression cassette, 1,835 bp; a HindIII 9,063-bp fragment of C346 cosmid (nucleotides 12,421-21,484 in gb:L31948); and the right-end terminus of Ad5, composed of the ITR sequence, 117 bp (nucleotides 35,818-35,935); with the intervening multiple cloning sites between junctions of the different fragments the total size is 19.6 kb including 2.9 kb to the pBluescript IIKS. The 2.9 kb of pBluescript IIKS is eliminated before HD vector rescue by linearizing the plasmid with two PmeI flanking sites. HD-leptin-monomer plasmid (pSTK120-HCMV-mOb-BGHpA) differs in that the hypoxanthine guanine phosphoribosyltransferase “stuffer” is a larger fragment of 16,054 bp (nucleotides 1,799-17,853 in gb:humhprtb), total size ≈30 kb including 2.9 kb of the pBluescript IIKS, which as in the case of HD-leptin plasmid, is also eliminated by linearizing the plasmid with two PmeI flanking sites and releasing the HD-leptin-monomer fragment.
Propagation of the HD Viruses.
For propagation of the HD viruses, we used a helper virus system consisting of a modified first-generation E1-deleted vector with lox sites flanking the packaging signals (AdLC8clucl), and a 293 cell line derivative expressing Cre recombinase (293-cre4) (Parks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A. & Graham, F. L. (1996) Proc. Natl. Acad. Sci. USA 93, 13565-13570; Chen, L., Anton, M. & Graham, F. L. (1996) Som. Cell Mol Genet. 22, 477-488.). HD-leptin Vector DNA was excised from the plasmid backbone (by PmeI digestion) and 4 μg were used to transfect semiconfluent 293-cre4 cells in 6-cm plates. After an overnight incubation, cells were infected at a multiplicity of infection of 1 with the helper virus AdLC8clucl. Cells were monitored for complete cytopathic effect, at which point cells were collected and lysate was used for serial propagation and expansion of viral stock by slight modification over what was described (Parks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A. & Graham, F. L. (1996) Proc. Natl. Acad. Sci. USA 93, 13565-13570; Parks, R. J. & Graham, F. L. (1997) J. Virol. 71, 3293-3298.). Two ml of lysate collected from P1 (transfection/infection step) was used to infect 6-cm plates of semi-confluent 294-cre4 for 24 hours, supplemented with 1 ml of fresh medium. After the 24-hr incubation, the helper virus AdLC8cluc1 was added at a multiplicity of infection of 1, to the cells. P2 lysate was collected upon detection of cytopathic effect. The same procedure was repeated for another three propagation's (P3, P4, and P5) infecting 10-cm plates followed by 15-cm plates of semiconfluent 293-cre4 cells, respectively. Lysate collected from P4 was used to infect twenty 15-cm plates (1 ml of lysate added to 24 ml of fresh medium), and again upon detection of cytopathic effect the lysate was collected and cesium chloride banded as described (Graham F. L. & Prevec, L. (1991) in Gene Transfer and Expression Protocols., ed. Murray, E. J. (Humana, Clinton, N.J.), pp. 109-128.). The banded viruses were analyzed by restriction mapping and the HD-leptin virus was sequenced for verification of structure.
The final stock of HD-leptin was harvested from ≈1.2×109293-cre4 cells and the cesium chloride banded viral stock yield was ≈8×1012 particles (2×1012/ml). The helper virus (AdLC8clucl) content in the HD-leptin stock was 1.5×107 plaque-forming units per ml. Fifty microliters (1-2×1011 OD particles per dose, containing ≈7.5×105 plaque-forming units helper, i.e., <0.1% contamination with helper per estimated infectious HD dose) of the stock were diluted with dialysis buffer to 100 μl for the mouse tail vein injections.
Repeat of HD-Leptin Viral Rescue.
Three independent rescues of the HD-leptin recombinant virus, initiated at the first step (P1), which is the transfection of pΔSTK120-HCMV-mOb-BGHpA resulted in an identical, and stable structure of HD-leptin. Seven different enzymes were used for verifying the structures of the recombinant HD viruses; Asp-718, EagI, FseI, HindIII, PacI, SmaI, and XhoI. Digested viral DNA (50-100 ng) was analyzed by Southern blot analysis, fragments were radiolabled using T4 DNA poymerase, DNA fragments were viewed on a 1.0 or 0.5% (for sizing purposes in case of undigested DNA extracted from HD-leptin and Ad-leptin) aragose gels in Tris/acetate/EDTA (TAE) buffer, and identified by radioautography or ethidium bromide staining.
PCR Amplification of the Junction Fragment and Sequencing.
A primer flanking the junction fragment was used for PCR, primer J4-F:5′-CTCTTCTTCTGTCACACCCCTCCCUC-3′ (SEQ NO:1) was used individually to amplify the junction-fragment of HD-leptin, the fragment generated was ˜300 bp, and was cloned into PCR 2.1 vector (Invitrogen) and sequenced.
Mouse Colony.
ob/ob (C57BL/J6-ob/ob) mice and homozygous normal lean (C57BL/J6) litter mates (age-matched females), were purchased from The Jackson Laboratory for use in this study. Animals were free of all common murine pathogens. Eight-to twelve-week-old mice (ob/ob≈70 g and lean≈28 g) were redistributed based on equal representation of weight and caged in groups of five on day 0, immediately preceding treatment. After a series of baseline blood samples were obtained by tail incision from conscious mice, animals were divided into four groups and received by tail vein injection a single 100-μl aliquot containing 1-2×1011 particles of HD-leptin, Ad-leptin, Ad-β-gal (control), or dialysis buffer (control). Body weight and food intake were measured daily, and blood was collected 2-3 times weekly, pre- and post-treatment.
Animals were killed by carbon dioxide inhalation and organs removed for immunohistochemistry and RNA analysis. All animals used in this study were maintained in accordance with the “Guide for the Care and Use of Laboratory Animals” (Institute for Laboratory Animals Resources, National Research Council, 1996). The protocol was approved by the Institutional Animal Care and Use Committee, Merck.
Histopathology Studies.
Mice (n=3 per treatment per time point) were humanely killed, and liver samples were collected and fixed in 10% buffered formalin. Tissues were routinely processed through paraffin, sectioned at 5 microns, and stained with hematoxylin and eosin. Replicate slides also were prepared using standard procedures for immunohistochemistry and stained for the presence of CD3 (T cell) and CD45R (B cell) determinants of infiltrating or intrinsic cells (not shown).
Blood Measurements.
Blood samples were obtained by tail incision and collected into heparinized microchematocrit tubes (VWR Scientific) every 2-3 days during the course of the study. Tubes were centrifuged at 13,700×g for 2 min, and hematocrit values were monitored. Plasma was collected for measurement of asparate, aminotransferase (AST), alanine aminotransferase (ALT), leptin, glucose, and insulin levels. ALT and AST were measured using ALT/serum glutamic oxaloacetic transaminase and AST/serum glutamic pyruvic transaminase, DT slides, respectively (Vitros Chemistry Products, Johnson & Johnson). Leptin and insulin levels were measured by radioimmunoassay performed by Linco Research Immunoassay (St. Charles, Mo.). Glucose levels were measured using Kodak Ektachem DT slides (Eastman Kodak).
Northern and Southern Blot Analysis.
For Northern blot analysis, total RNA was extracted (Trizol, GIBCO) from livers of Ad-leptin-treated and HD-leptin-treated mice at 1-, 2-, 4-, and 8-week intervals, and untreated mice. Leptin RNA message was detected by Northern blot analysis (Maniatis, T., Fritsch, E. F. & Sambrook, J. (1982) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Lab. Press, Plainview, N.Y.) using leptin cDNA as a probe that recognizes a single ≈500 bp band (Morsey, M. A., Gu, M., Zhao, J. Z., Holder, D. J., Rogers, I. T., Pouch, W., Motzel, S. L., Klein, H. J., Gupta, S. K., Liang, X., et al. (1998) Gene Ther. 5, 8-18). A probe for β-actin was used as the internal control (≈1 kb) (Biochain, San Leandro, Calif.). Southern blot analysis (Maniatis, T., Fritsch, E. F. & Sambrook, J. (1982) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Lab. Press, Plainview, N.Y.) was used to investigate the stability of vector DNA. Genomic DNA was extracted from livers (pooled DNA, n=3) per treatment per time period) of ob/ob and lean mice were treated with Ad-β-gal, Ad-leptin or HD-leptin. Control animals were injected with similar volumes of dialysis buffer. Pooled (n=3) genomic DNA was digested with HindIII restriction enzyme, and 20 μg of digested DNA were loaded on 0.8% TAE agarose gels. For copy number estimation, 20 μg control DNA were spiked with HD vector DNA equivalent to 2.0, 1.0, 0.2, and 0.1 copies per cell, and the mixture digested with HindIII restriction enzyme followed by Southern blot analysis. The filters were hybridized with a mouse leptin cDNA (≈500 bp) probe, which hybridized to a single HindIII fragment containing the leptin insert in both the HD-leptin (≈6 kb), and Ad-leptin (≈1.2 kb) vectors. Developed autoradiographs were scanned (Personal Densitometer SI, Molecular Dynamics) and the relative band densities quantitated (IMAGE QUANT software, Molecular Dynamics). To normalize DNA concentration and to estimate relative vector DNA stability between treatment time points, a detected internal leptin genomic DNA signal was used as control. Copy number equivalence were assigned based on comparisons to the relative density ratio between the internal genomic signal and the leptin signal of spiked vector DNA in a copy number control experiment.
Results and Discussion
The HD viruses rescued and propagated were analyzed both for structure verification and for helper-load contamination. HD-leptin (used in this study) was generated from a 16.7-kb vector fragment (
In contrast, the HD-leptin monomer, containing a single copy of the packaging signal sequence at the left arm only, consistently results in at least 3-10 fold higher load of helper virus contamination (1 plaque-forming unit of helper virus per 103-104 OD particles per ml) in HD-leptin monomer stock. Given that all the various viral stocks were prepared following the same standard laboratory procedures, the consistently lower levels of helper contamination in the concatamerized HD-leptin viral stock may be attributed to either the duplicated copy of packaging signal sequence or the differences in backbone composition, possibilities now under investigation.
As a first measure of the difference between first generation Ad and HD vectors, safety studies were conducted in control and treated lean and ob/ob mice. Mice were treated with a single tail intravenous infusion of 1-2×1011 particles of either HD-leptin, Ad-leptin, control Ad-β-gal vector or an equal volume of dialysis buffer.
Liver sections of HD-leptin-treated lean mice (
In the lean mice, treatment with Ad-leptin resulted in a transient increase in serum leptin levels and weight loss that lasted for only 7-10 days (
The ob/ob mice are naïve to leptin and thus transgene immunogenicity is not an unexpected finding. In these animals, similar to what was observed in the lean mice, HD-leptin was found to be more effective than the first-generation Ad-leptin vector. In the ob/ob treated with Ad-leptin, serum levels of leptin increased only for a short period during in first 4 days of treatment, returning to baseline levels within 10 days of postinjection (
It has been reported that Ad vectors and/or immunogenic transgenes can be associated with cytotoxic T lymphocyte cell responses that result in elimination of vector DNA infected cells and loss of gene expression (Yang, Y., Nunes, F. A., Berensci, K., Furth, E. E., Gonczol, E. & Wilson, J. M. (1994) Proc. Natl. Acad. Sci. USA 91, 4407-4411; Yang, Y., Ertl, H. D. & Wilson, J. M. (1995) J. Virol. 69, 2004-2015; Lochmuller, H., Petrof, B. J., Pari, G., Larochelle, N., Dodelet, V., Wang, Q., Allen, C., Prescott, S., Massie, B., Nalbantoglu, J., et al. (1996) Gene Ther. 3, 706-716; Gahery-Segard H., Juilliard, V., Gaston, J., Lengagne, R., Pavirani, A., Boulanger, P. & Guillet, J. G. (1997) Eur. J. Immunol. 27, 653-659; Kajiwara, K., Byrnes, A. P., Charlton, H. M., Wood, M. J. & Wood K. J., (1997) Hum. Gene Ther. 8, 45-56; Kaplan, J. M., Armentano, D., Sparer, T. E., Wynn, S. G., Peterson, P. A., Wadsworth, S. C., Couture, K. K, Pennington, S. E., St. George, J. A., Gooding, L. R. & Smith, A. E. (1997) Hum. Gene Ther. 8, 45-46; Worgall, S., Wolff, G., Falck-Pedersen, E & Crystal, R. G. (199) Hum. Gene Ther. 8, 37-44; Tripathy, S. K., Black, H. B., Goldwasser, E & Lieden, J. M. (1996) Nat. Med. 2, 545-550.). In some case the response is influenced by the mouse strain used (Tripathy, S. K., Black, H. B., Goldwasser, E. & Lieden, J. M. (1996) Nat. Med. 2, 545-550.). In this study we used littermates to control against strain variation in our comparisons of the Ad-vector vs. the HD-vector immunogenicity in both lean animals that normally express leptin and ob/ob mice that are leptin different. Our studies clearly illustrate that HD-leptin achieved a substantial improvement in the safety profile and longevity of gene expression over that achieved with the first-generation Ad-leptin vector. The differences observed in the extent of cellular infiltrate in the liver, together with the pronounced liver toxicity as measured by ≈10- and 5-fold increases in AST and ALT serum values, respectively, associated with Ad-leptin but not HD-leptin treatment in lean mice, can be directly attributed to the elimination of the Ad protein-coding DNA sequences, because the leptin expression cassette was identical in both vectors, the appearance of a leptin-specific antibody response, gradual loss of gene expression and vector DNA observed in the ob/ob (leptin-deficient) but not in the lean mice (leptin-wild type) treated with HD-leptin may suggest an independent immune response event related to leptin tolerance.
The leptin model used in these studies provided a very instructive animal model to investigate the influence of both vector design and transgene product on the duration of expression after gene transfer. The differences between the longevity of expression mediated by the HD-deleted vector in the lean mice in this study and the very short lived effects reported by others may reflect variations in the vector construction features (Lieber, A., He, C., Kirillova, I. & Kay, M. A. (1996) J. Virol. 70, 8944-8960; Sykes, R. C., Lin, D., Hwang, S. J., Framson, P. E. & Chinault, A. C. (1998) Mol. Gene. Genet.I 212, 301-309.).
The HD-vector system is a significant advance over existing Ad vectors with regards to safety and insert capacity (up to 37 kb). In addition to the gain of these two valuable properties, the HD vectors have not lost the features that contributed to the general attractiveness of Ad vectors that include: (i) efficient in vivo gene delivery, and (ii) high titer production. The concatamerization of the 16.7 vector fragment to generate a ≈33 kb recombinant virus is a phenomenon that has been previously observed by others (Fischer, K. J., Choi, H., Burda, J., Chen, S. & Wilson, J. M. (1996) Virology 217, 11-22; Parks, R. J., & Graham, F. L. (1996) J. Virol. 71, 3293-3298.). The recombinant virus preferentially propagates at higher efficiences when its genome length is at least 75% that of wild type (Parks, R. J., & Graham, F. L. (1996) J. Virol. 71, 3293-3298.). And although we detected traces of propagated 16.7 kb HD-leptin, the prevalence of this species was overwhelmingly surpassed by the 33-kb recombinant vector (
Replacements of leptin by other transgenes in the pΔSTK120 are ongoing to determine the universality of this vector backbone. The generation of other backbones with the duplicated left arm is being tested to determine the extent to which the two copies of packaging signal sequences is contributing to the efficient propagation and possible advantage of the HD-recombinant virus over the helper virus leading to the exceedingly low levels of helper contamination in the HD stocks. The unique characteristics of HD-leptin together with the utilization of the 293-cre4 cells and the lox containing helper virus provides a biological method for generation of highly purified HD vectors. These advanced vectors improve the prospect of Ad vehicles for wide application in clinical gene therapy.
The minimal FRT DNA sequence is a 34 bp DNA segment that is readily produced as a synthetic deoxyoligonucleotide that can be inserted into plasmid or viral DNA (see
An independent measure of the efficiency of excision of a DNA segment flanked by FRT sites was obtained by direct analysis of DNA structure using Southern blot analysis. Cells were infected with Adlucneofrt, Adlucfrt or were coinfected with Adlucneofrt and AdFLP and DNA was extracted 27 h post infection, digested with StuI or HindIII restriction enzymes, and transferred onto nitrocellulose membranes and probed with a labelled DNA that hybridized to neo and luciferase sequences. The structures of the Adlucneofrt virus and the probe are illustrated in
Plasmids were constructed containing FLP recombinase and encoding hygromycin resistance for transformation of cells to obtain cell lines expressing high concentrations of FLP. In the example illustrated in
293 and 293Cre cells were transfected with pCBFLPHY and selected for hygromycin resistance by incubation in hygromycin at various concentrations ranging from 200 to 600 μg/ml. Transformed colonies were isolated and expanded and screened for FLP expression using the assay described in Example 2. results of a typical experiment are illustrated in
To produce a helper virus containing a packaging signal flanked by FRT sites the method illustrated in
Further study of the DNA structure in the virus infected cells was carried out by Southern blot analysis of the gel shown in
Since all of the methodology described herein is essentially that employed in the production of the original 293 Cre cells and the results of all analyses are identical to results obtained with the Cre-lox system, and since there is ample space for insertion between the ITR and the packaging signal of a combination of loxP and FRT sites, and since we have demonstrated that 293Cre cells can be transformed to express FLP in addition to Cre, those skilled in the art will appreciate from the present disclosure that not only can 293 Cre/FLP cells can be produced and used to excise sequences flanked by FRT sites, but 293 Cre/FLP cells can be produced and used to excise sequences flanked by lox sites, FRT sites or both, and in addition, cells may be produced which encode other recombinases for use with other site-specific recognition sites according to the present methodology. Thus constructs can be prepared wherein several site-specific recombinase target sites are used to flank a sequence, the excision of which is described. LoxP sites flanking a first sequence, FRT sites flanking a second sequence, or loxP and FRT sites flanking a particular sequence are all strategies which may be employed, such that upon expression of the relevant recombinase, (Cre, FLP or like recombinase), the relevant sequence is excised. Use of multiple recognition sites and recombinases in a given construct provides redundancy and fail-safe methodology when certainty and high-efficiency target site excision is critical. Accordingly, this Invention enables the production of FLP based helper viruses or FLP+Cre based helper viruses and vectors which employ Cre-FLP or other recombinase systems and combinations thereof.
The cells of this invention are useful not only in the production of helper dependent adenovirus vectors but also have utility in a number of other applications. For example, host cells expressing site specific recombinases are useful for a variety of different purposes where regulation of gene expression through site specific recombination is desired. As described in Anton, M. and Graham, F. L. Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression. J. Virol. 69:4600-4606, 1995 (Anton and Graham), in Chen, L., Anton, M. and Graham, F. L. Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat. Cell and Molec. Genet. 22: 477-488, 1996 (Chen) and in U.S. Pat. Nos. 6,974,694 and 6,120,764, all of which are incorporated by reference for the specific teachings, plasmids and viral vectors can be designed and constructed comprising expression cassettes with genes whose expression is regulated by site specific recombination. Said plasmids and viral vectors can be introduced into host cells stably expressing the site specific recombinases and site specific recombination will regulate gene expression from said cassettes. For example, not meant to be limiting, one skilled in the art can readily construct a plasmid or viral vector comprising an inserted expression cassette comprising a promoter sequence, a coding sequence of a gene, and a transcription termination site, and site-specific recombinase target sites positioned to remove or invert a portion of the expression cassette so that expression of the coding sequence is increased or reduced relative to levels of expression obtained in the absence of recombination. A specific example, not meant to be limiting, of a cassette from which expression would be decreased following recombination would be one in which the cassette comprises a promoter sequence, a coding sequence of a gene, and a transcription termination site, and site-specific recombinase target sites flanking the promoter sequence of said expression cassette that promotes expression of the gene. Another example, not meant to be limiting, is a cassette comprising a promoter sequence, a coding sequence of a gene, a DNA spacer sequence located between the promoter sequence and the coding sequence, and a transcription termination site, and site-specific recombinase target sites flanking the DNA spacer sequence, wherein recombination between said target sites mediated by a site-specific recombinase removes the DNA spacer sequence, resulting in increased expression of the coding sequence of the gene. Numerous additional examples of cassettes whose expression is regulatable by site specific recombination are described in Anton and Graham, in Chen and in U.S. Pat. Nos. 6,974,694 and 6,120,764 or can be constructed by one skilled in the art. Furthermore, one skilled in the art can readily introduce such cassettes, whether in plasmid DNA, viral DNA or as expression cassettes themselves without extraneous DNA sequences, into the host cells described in this invention, wherein site specific recombination provides the desired regulation of gene expression from the introduced cassette.
This application is a continuation-in-part of application Ser. No. 10/206,163, filed Jul. 26, 2002, now pending, which is a continuation-in-part of application Ser. No. 09/351,819, filed Jul. 13, 1999, now abandoned, which is a continuation-in-part of application Ser. No. 09/251,955, filed on Feb. 17, 1999, now abandoned, which is a continuation-in-part of application Ser. No. 08/473,168, filed on Jun. 7, 1995, now issued as U.S. Pat. No. 5,919,676. The benefit of priority under 35 USC 119 and/or 120 is claimed for all of the above applications, and each of these applications is hereby incorporated by reference.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10206163 | Jul 2002 | US |
| Child | 11323936 | Dec 2005 | US |
| Parent | 09351819 | Jul 1999 | US |
| Child | 10206163 | Jul 2002 | US |
| Parent | 09251955 | Feb 1999 | US |
| Child | 09351819 | Jul 1999 | US |
| Parent | 08473168 | Jun 1995 | US |
| Child | 09251955 | Feb 1999 | US |
